New Cell Therapy Shows Promise for Treating Frailty in Elderly, India's Health System Needs Adaptation
A new international study published in Cell Stem Cell indicates that a single infusion of mesenchymal stem cells (Lomecel-B) significantly improves physical endurance in frail elderly individuals. Frailty, a state of accelerated biological ageing affecting one in four people over 50 globally, currently lacks a standard treatment protocol. While promising, the therapy's mechanism involves reducing inflammation and promoting tissue repair. For India, with its rapidly aging population, the findings highlight the need for its health system to shift from acute illness focus to preventive geriatric care, recognizing frailty as a treatable condition and adapting policies like Ayushman Bharat and ICMR guidelines for stem cell therapies.
मुख्य बिंदु
- A new study suggests that mesenchymal stem cell therapy can biologically treat frailty in the elderly, improving physical endurance.
- Frailty is defined as accelerated biological ageing, affecting a significant portion of the global elderly population.
- Mesenchymal stem cells work by reducing inflammation and promoting tissue repair, without strongly activating the immune system.
- India's health system needs to adapt to address frailty, shifting focus from acute illness to preventive geriatric care and recognizing frailty as a treatable condition.
- Further large-scale clinical trials, including bridging trials for Indian populations, are required before widespread clinical use.
परीक्षा तथ्य
- The study was part of Phase IIb of the CRATUS trial.
- The findings were published in the journal Cell Stem Cell on March 5.
- The mesenchymal stem cell product is called Lomecel-B (or laromestrocel).
- India's population aged 60 and over is projected to rise to nearly 20% by 2050.
- The Indian Council of Medical Research (ICMR) has guidelines for stem cell use.
पढ़ें। याद रखें। याद करें।
स्पेस्ड-रिपीटिशन फ्लैशकार्ड, दैनिक क्विज़ और ऑफ़लाइन एक्सेस पाएं — एंड्रॉइड पर मुफ़्त।